Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.51 |
| ▸ | LOX | P28300 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9502722 | 0.84 | ALOX5 (0.59) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL1444768 | 0.81 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL8875123 | 0.81 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL8876780 | 0.81 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL8933733 | 0.80 | ALOX5 (0.56) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL8895495 | 0.79 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL10701339 | 0.76 | ALOX5 (0.45) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL13619726 | 0.76 | ALOX5 (0.49) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Hydroxyurea SCHEMBL6391315 | 0.75 | ALOX5 (0.57) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Hydroxyurea SCHEMBL9602586 | 0.75 | ALOX5 (0.57) | ALOX5CYP1A2PTGESLMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2558474-B1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2501705-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8642593-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8618095-B2 | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130150329-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8389515-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2558474-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| WO-2011130390-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110124599-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
| US-20100041678-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20090306028-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20070117775-A1 | Compositions and Methods For Treating Inflammatory Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041678-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | SYK, IRAK2, IRAK4 | ALOX5 287/4885CYP1A2 3709/4885PTGES 267/4885 |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | ALOX5 1574/4885CYP1A2 4335/4885PTGES 1487/4885 |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | TYMP, DPYD, TYMS | ALOX5 1684/4885CYP1A2 366/4885PTGES 1941/4885 |
| US-20110124599-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | DPYD, TYMP, PNP | ALOX5 1883/4885CYP1A2 358/4885PTGES 2272/4885 |
| US-20130150329-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | DPYD, TYMP, PNP | ALOX5 1883/4885CYP1A2 358/4885PTGES 2272/4885 |
| US-20090306028-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | SYK, IRAK2, IRAK4 | ALOX5 254/4885CYP1A2 3922/4885PTGES 196/4885 |
| US-20070117775-A1 | Compositions and Methods For Treating Inflammatory Disorders | SYK, IRAK2, IRAK4 | ALOX5 254/4885CYP1A2 3922/4885PTGES 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.